Clinical Trial

Heparin Anticoagulation in Septic Shock

Study Description

Heparin Anticoagulation in Septic Shock

This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.


Locations Selected Location


Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Unfractionated heparin

UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis acco more on

Venous thromboprophylaxis (VTE)

May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings

Additional Information

Official Study Title

Heparin AnticoaguLation to Improve Outcomes in Septic Shock: The HALO International Phase II RCT

Clinical Trial ID


ParticipAid ID